Selpercatinib is a novel agent which received accelerated approval in 2020 for the treatment of RET-mutant malignancies including nonsmall cell lung cancer, medullary thyroid cancer, and other RET-fusion positive thyroid malignancies.1 Here, RET is linked to thyroiditis.